Armed with convenience and lower price, Adtralza targets Dupixent’s market stronghold
LEO Pharma's Adtralza (tralokinumab), covered by health insurance from this month for treating chronic severe atopic dermatitis in adults and adolescents with at least three years of disease, now aims to target the market with convenience and economic …